MA53009A - Agents inhibiteurs d'ask1 - Google Patents
Agents inhibiteurs d'ask1Info
- Publication number
- MA53009A MA53009A MA053009A MA53009A MA53009A MA 53009 A MA53009 A MA 53009A MA 053009 A MA053009 A MA 053009A MA 53009 A MA53009 A MA 53009A MA 53009 A MA53009 A MA 53009A
- Authority
- MA
- Morocco
- Prior art keywords
- ask1 inhibitors
- ask1
- inhibitors
- Prior art date
Links
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 title 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690674P | 2018-06-27 | 2018-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53009A true MA53009A (fr) | 2021-05-05 |
Family
ID=67254023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053009A MA53009A (fr) | 2018-06-27 | 2019-06-26 | Agents inhibiteurs d'ask1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11814362B2 (fr) |
| EP (1) | EP3814333B1 (fr) |
| JP (1) | JP2021528456A (fr) |
| KR (1) | KR20210024532A (fr) |
| CN (1) | CN112638896A (fr) |
| AR (1) | AR115636A1 (fr) |
| AU (1) | AU2019291806A1 (fr) |
| BR (1) | BR112020026423A2 (fr) |
| CA (1) | CA3104662A1 (fr) |
| CL (1) | CL2020003375A1 (fr) |
| CO (1) | CO2021000782A2 (fr) |
| CR (1) | CR20210049A (fr) |
| EA (1) | EA202190034A1 (fr) |
| ES (1) | ES3032286T3 (fr) |
| IL (1) | IL279709A (fr) |
| JO (1) | JOP20200318A1 (fr) |
| MA (1) | MA53009A (fr) |
| MX (1) | MX2020013895A (fr) |
| PE (1) | PE20211379A1 (fr) |
| SG (1) | SG11202012784SA (fr) |
| TW (1) | TW202035389A (fr) |
| UY (1) | UY38278A (fr) |
| WO (1) | WO2020006031A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231253T1 (hr) | 2018-06-27 | 2024-02-02 | Bristol-Myers Squibb Company | Supstituirani spojevi naftiridina korisni kao aktivatori t stanica |
| JP2021528456A (ja) | 2018-06-27 | 2021-10-21 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ａｓｋ１阻害剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| CR20160268A (es) * | 2013-12-20 | 2016-08-16 | Gilead Sciences Inc | Inhibidores de la quinasa reguladora de la señal de apoptosis |
| WO2018151830A1 (fr) * | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Inhibiteurs de kinase de régulation du signal apoptotique à base de pyridinyle |
| JP2021528456A (ja) | 2018-06-27 | 2021-10-21 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ａｓｋ１阻害剤 |
-
2019
- 2019-06-26 JP JP2020572645A patent/JP2021528456A/ja active Pending
- 2019-06-26 UY UY0001038278A patent/UY38278A/es not_active Application Discontinuation
- 2019-06-26 CA CA3104662A patent/CA3104662A1/fr not_active Abandoned
- 2019-06-26 BR BR112020026423-7A patent/BR112020026423A2/pt not_active Application Discontinuation
- 2019-06-26 AU AU2019291806A patent/AU2019291806A1/en not_active Abandoned
- 2019-06-26 SG SG11202012784SA patent/SG11202012784SA/en unknown
- 2019-06-26 JO JOP/2020/0318A patent/JOP20200318A1/ar unknown
- 2019-06-26 US US17/253,269 patent/US11814362B2/en active Active
- 2019-06-26 WO PCT/US2019/039156 patent/WO2020006031A1/fr not_active Ceased
- 2019-06-26 CR CR20210049A patent/CR20210049A/es unknown
- 2019-06-26 KR KR1020217000614A patent/KR20210024532A/ko not_active Withdrawn
- 2019-06-26 AR ARP190101780A patent/AR115636A1/es not_active Application Discontinuation
- 2019-06-26 ES ES19739494T patent/ES3032286T3/es active Active
- 2019-06-26 TW TW108122356A patent/TW202035389A/zh unknown
- 2019-06-26 EA EA202190034A patent/EA202190034A1/ru unknown
- 2019-06-26 CN CN201980042586.9A patent/CN112638896A/zh active Pending
- 2019-06-26 MA MA053009A patent/MA53009A/fr unknown
- 2019-06-26 PE PE2020002138A patent/PE20211379A1/es unknown
- 2019-06-26 EP EP19739494.3A patent/EP3814333B1/fr active Active
- 2019-06-26 MX MX2020013895A patent/MX2020013895A/es unknown
-
2020
- 2020-12-23 IL IL279709A patent/IL279709A/en unknown
- 2020-12-23 CL CL2020003375A patent/CL2020003375A1/es unknown
-
2021
- 2021-01-25 CO CONC2021/0000782A patent/CO2021000782A2/es unknown
-
2023
- 2023-10-05 US US18/377,125 patent/US12404263B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL279709A (en) | 2021-03-01 |
| US20240109867A1 (en) | 2024-04-04 |
| CA3104662A1 (fr) | 2020-01-02 |
| WO2020006031A8 (fr) | 2020-09-24 |
| TW202035389A (zh) | 2020-10-01 |
| AR115636A1 (es) | 2021-02-10 |
| WO2020006031A1 (fr) | 2020-01-02 |
| US12404263B2 (en) | 2025-09-02 |
| CO2021000782A2 (es) | 2021-01-29 |
| PE20211379A1 (es) | 2021-07-27 |
| AU2019291806A1 (en) | 2021-01-07 |
| EP3814333B1 (fr) | 2025-03-19 |
| US11814362B2 (en) | 2023-11-14 |
| SG11202012784SA (en) | 2021-01-28 |
| JP2021528456A (ja) | 2021-10-21 |
| US20210115020A1 (en) | 2021-04-22 |
| CL2020003375A1 (es) | 2021-09-03 |
| KR20210024532A (ko) | 2021-03-05 |
| BR112020026423A2 (pt) | 2021-03-23 |
| EA202190034A1 (ru) | 2021-04-08 |
| UY38278A (es) | 2020-01-31 |
| JOP20200318A1 (ar) | 2020-12-10 |
| EP3814333A1 (fr) | 2021-05-05 |
| CR20210049A (es) | 2021-07-01 |
| MX2020013895A (es) | 2021-07-21 |
| CN112638896A (zh) | 2021-04-09 |
| ES3032286T3 (en) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| EP3906026A4 (fr) | Inhibiteurs irréversibles de l'interaction ménine-mll | |
| DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
| EP3735685A4 (fr) | Panneau d'affichage | |
| EP3784285C0 (fr) | Agents cryoprotecteurs pour formulations particulaires | |
| EP3843714C0 (fr) | Inhibiteurs de cd73 | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| EP3750149C0 (fr) | Panneau d'affichage | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| UA42295S (uk) | Комп'ютер | |
| EP3798719A4 (fr) | Panneau d'affichage | |
| UA42369S (uk) | Комп'ютер | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| EP3919491A4 (fr) | Inhibiteur d'akt | |
| EP3532240A4 (fr) | Base d'outillage | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| EP3992176A4 (fr) | Antagoniste d'ep2 | |
| MA50906A (fr) | Inhibiteurs d'immunoprotéasome | |
| EP3765619A4 (fr) | Inhibiteurs de micro-arn 22 | |
| EP3863629A4 (fr) | Promédicaments d'antagonistes du cgrp | |
| IL269695A (en) | Compounds useful as inhibitors of alcat 1 | |
| EP3794015A4 (fr) | Agents d'activation | |
| EP3815846A4 (fr) | Machine d'entraînement |